PDCD1 and nasopharyngeal carcinoma: Here, we comprehensively investigated the value of plasma EBV DNA titers and their dynamics as biomarkers for predicting long-term outcomes and monitoring disease progression by analyzing the data from a prospective clinical study with the largest cohort to date of patients with RM-NPC treated with anti–PD-1 monotherapy.